We observed that drug sensitivity was significantly proportional to DNA methylation levels of the PTPRM gene promoter in pancreatic cancer cell lines (rho = 0.3, P = 0.00462) (Fig. 5C) suggesting that PTPRM promoter methylation profiles maybe used as a potential biomarker for clinical treatment response in pancreatic cancer patient therapy. This evidence concerns the gene PTPRM and familial pancreatic carcinoma.